Indirect Bilirubin Test

Your body destroys and replaces millions of red blood cells every day. As each cell is broken down, a yellow pigment called bilirubin is released into your bloodstream. This form, called indirect bilirubin (unconjugated bilirubin), travels bound to a blood protein called albumin until your liver can pick it up, chemically modify it, and send it out through bile. Indirect bilirubin tells you whether that entire chain, from red blood cell breakdown to liver processing, is keeping pace.

What makes this measurement uniquely useful is that it separates two very different stories. A rise in indirect bilirubin points toward either too many red blood cells being destroyed or a liver that is slow to process the pigment. That distinction matters, because the causes, risks, and next steps are completely different from those triggered by a rise in direct (conjugated) bilirubin, which signals liver or bile duct disease. Standard lab panels often report only total bilirubin, which blurs these two stories together.

What Indirect Bilirubin Reflects

Indirect bilirubin is not measured directly by the lab. Instead, the lab measures total bilirubin and direct bilirubin, then calculates indirect bilirubin by subtracting one from the other. The result reflects three biological processes happening simultaneously: how fast your body is breaking down red blood cells and releasing their heme pigment, how efficiently your liver cells are pulling that pigment out of the blood, and how well a liver enzyme called UGT1A1 is converting it into a water-soluble form that can be excreted in bile.

In a healthy person, roughly 70% of total serum bilirubin is the indirect form. When indirect bilirubin climbs above normal, it means one of those three processes has shifted: production is up, uptake is down, or the conversion enzyme is underperforming. Each scenario has a different cause and a different clinical path.

Gilbert Syndrome: The Most Common Cause of Mild Elevation

If your indirect bilirubin is mildly elevated and the rest of your liver enzymes are normal, the most likely explanation is a harmless genetic condition called Gilbert syndrome. It affects 3% to 7% of the U.S. population and results from a variant in the UGT1A1 gene that reduces the liver's bilirubin-processing enzyme to about 30% of normal activity. Total bilirubin in Gilbert syndrome usually stays below 4 mg/dL and rarely exceeds 6 mg/dL.

Gilbert syndrome requires no treatment and no further workup in asymptomatic individuals with mild unconjugated hyperbilirubinemia (below 4 mg/dL) and normal liver enzymes, according to the American College of Gastroenterology. Fasting, stress, or illness can temporarily push bilirubin two to three times higher than baseline in people with this variant, which is why you might see your number spike during a period of skipped meals or acute illness and then return to normal.

Hemolytic Disorders: When Red Blood Cells Break Down Too Fast

A more serious cause of elevated indirect bilirubin is hemolysis, a condition in which red blood cells are destroyed faster than normal. Conditions like sickle cell disease, thalassemia, hereditary spherocytosis, and G6PD deficiency can all drive up indirect bilirubin through excess red blood cell breakdown. However, hemolysis alone rarely pushes bilirubin above 5 mg/dL unless kidney disease, liver disease, or severe acute hemolysis is also present.

When hemolysis is suspected, your indirect bilirubin result is interpreted alongside other markers: low haptoglobin (a protein that drops when it binds free hemoglobin released from destroyed red cells), elevated reticulocyte count (immature red blood cells, reflecting the bone marrow working overtime), and elevated LDH (an enzyme released when cells are damaged). The pattern across all four markers, not indirect bilirubin alone, confirms the diagnosis.

Cardiovascular Protection: The Unexpected Upside of Mild Elevation

One of the more surprising findings in bilirubin research is that mildly elevated levels appear to protect against heart disease. A meta-analysis pooling 12 prospective studies with 9,378 cardiovascular events found that each standard-deviation increase in total bilirubin was associated with a 7% lower risk of cardiovascular disease after adjusting for standard risk factors. This inverse relationship held for both coronary heart disease and stroke.

A large UK Biobank analysis of over 331,000 participants used a technique called Mendelian randomization, which uses genetic variants as natural experiments to test cause and effect. This analysis found that genetically higher bilirubin was linked to an 8% lower risk of cardiovascular disease and a 10% lower risk of coronary heart disease, suggesting the relationship may be causal rather than just a statistical association.

The sweet spot for cardiovascular benefit appears to be a total bilirubin range of roughly 1.0 to 1.2 mg/dL (17 to 20 micromoles per liter), according to a dose-response meta-analysis of 12 studies covering 368,567 participants. Below that range, cardiovascular risk climbs. In a study of 130,052 statin-treated adults, those with total bilirubin around 0.3 mg/dL had 18% higher cardiovascular risk, 34% higher heart attack risk, and 33% higher all-cause mortality compared to those at 0.6 mg/dL.

The U-Shaped Pattern: Too Low Carries Risk Too

The cardiovascular data point to a U-shaped relationship: both very low and very high bilirubin levels are associated with worse outcomes, with a protective zone in between. The Dongfeng-Tongji cohort study of 12,097 adults confirmed this U-shaped pattern specifically for indirect bilirubin and coronary heart disease. Participants in the middle range (third quintile) had 24% lower coronary heart disease risk compared to those in the lowest quintile.

A study of over 4,300 older U.S. adults found the same pattern for mortality. Those with total bilirubin between 0.1 and 0.4 mg/dL had 36% higher mortality than those in the 0.5 to 0.7 mg/dL range. Emerging research frames low bilirubin as a potential sign of reduced antioxidant capacity, since bilirubin acts as one of your body's built-in damage-repair molecules. While specific thresholds defining a harmful low level remain under investigation, the direction of the evidence is consistent: unusually low bilirubin is not a reassuring finding.

Cancer Associations

The relationship between bilirubin and cancer is more complex and varies by cancer type. A Japanese case-cohort study of 3,584 cancer cases followed for nearly 16 years found that higher total bilirubin was associated with 14% lower total cancer risk when liver cancer was excluded. A Korean study of 78,467 adults found that those in the highest tertile of total bilirubin had 26% lower colorectal cancer risk over about 8 years of follow-up, with a U-shaped pattern in men showing the lowest risk around 0.8 mg/dL.

However, bilirubin's relationship with liver cancer runs in the opposite direction. The UK Biobank found that higher total bilirubin was associated with roughly double the risk of liver cancer. This likely reflects the fact that liver disease itself raises bilirubin, making it a marker of existing liver damage rather than a cause of cancer. When interpreting your own results, a mildly elevated indirect bilirubin in the context of normal liver enzymes does not signal liver cancer risk.

Reference Ranges

Indirect bilirubin values vary by sex, age, genetics, and the specific lab assay used. Males tend to have higher values than females. Individuals with Gilbert syndrome will have a persistently higher baseline that is normal for them. Always compare your results within the same lab over time for the most meaningful trend.

These tiers are drawn from published clinical guidelines and cardiovascular outcome data. Note that these values refer to total bilirubin, since indirect bilirubin is calculated from the total. Your lab may use different assays and cutpoints. Compare your results within the same lab over time for the most meaningful trend.

Tracking Your Trend

A single indirect bilirubin reading is a snapshot, and bilirubin's biological variability makes snapshots unreliable. The intra-individual coefficient of variation for total bilirubin is approximately 23.4%, meaning your result can swing meaningfully from one draw to the next due to normal biology alone. In one large study, 38% of adults with an initially elevated bilirubin had a normal result when retested just 17 days later. That means more than one in three "abnormal" results is a false alarm.

Bilirubin also follows a circadian rhythm, with levels peaking in the morning and varying by 12.8% to 42.5% within the same person depending on sleep patterns. If you are testing fasted, stressed, or after an unusual night of sleep, your result could be artificially high.

For a reliable baseline, get your first test under consistent conditions: same time of morning, non-fasted (or at least with a consistent fasting window), and not during acute illness. If your result is mildly elevated, repeat the test in two to four weeks under the same conditions before drawing conclusions. Once you have a stable baseline, annual retesting is reasonable. If you are making dietary or lifestyle changes that could affect red blood cell turnover or liver function, retest in three to six months to see whether your trend is moving.

When Results Can Be Misleading

Several common situations can shift your indirect bilirubin reading without reflecting a real change in your health. Given the 23.4% natural variability, a single borderline result should always be confirmed before acting on it.

• Fasting: skipping meals for 12 or more hours can increase unconjugated bilirubin by two to three times in people with Gilbert syndrome, and to a lesser degree in everyone else. If you fasted overnight before your draw, this alone could explain a mild elevation. Eating before retesting can help clarify whether the spike was real.
• Acute illness or surgery: any significant physiological stress can raise indirect bilirubin two to three times above baseline through the same mechanism as fasting. Wait until you have fully recovered before retesting.
• Time of day and sleep disruption: bilirubin peaks in the morning and fluctuates more when your sleep schedule is disrupted. Ideally, test at the same time of day each time, after a normal night of sleep.
• Statins: simvastatin and rosuvastatin can raise bilirubin modestly (roughly 10% to 15%) by affecting liver transport proteins. This is not a sign of liver damage and does not require stopping the medication, but it can shift your baseline upward.